




PHARMACEUTICAL 2023

Scopus BioPharma Inc.
Rank 446 of 446





PHARMACEUTICAL 2023

Scopus BioPharma Inc.
Rank 446 of 446

The relative strengths and weaknesses of Scopus BioPharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Scopus BioPharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 627% points. The greatest weakness of Scopus BioPharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 635% points.

The company's Economic Capital Ratio, given in the ranking table, is -836%, being 879% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	390
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,454
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	187
Other Expenses	9,033
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	2.3
Research and Development	2,682
Selling, General and Administrative Expense	9,033

Output Variable	Value in 1000 USD
Assets	392
Liabilities	7,454
Expenses	20,748
Revenues	0
Stockholders Equity	-7,062
Net Income	-20,748
Comprehensive Net Income	-20,655
Economic Capital Ratio	-836%